Timing of implant-removal in late acute periprosthetic joint infection: A multicenter observational study.
Aged
Aged, 80 and over
Algorithms
Arthritis, Infectious
/ diagnosis
Biomarkers
Device Removal
/ methods
Disease Management
Female
Humans
Male
Propensity Score
Prostheses and Implants
Prosthesis-Related Infections
/ diagnosis
Retrospective Studies
Severity of Illness Index
Survival Analysis
Treatment Outcome
Debridement
Failure
Hematogenous
Late acute
Periprosthetic joint infection
Revision surgery
Journal
The Journal of infection
ISSN: 1532-2742
Titre abrégé: J Infect
Pays: England
ID NLM: 7908424
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
18
04
2019
revised:
21
06
2019
accepted:
05
07
2019
pubmed:
19
7
2019
medline:
11
7
2020
entrez:
19
7
2019
Statut:
ppublish
Résumé
We evaluated the treatment outcome in late acute (LA) periprosthetic joint infections (PJI) treated with debridement and implant retention (DAIR) versus implant removal. In a large multicenter study, LA PJIs of the hip and knee were retrospectively evaluated. Failure was defined as: PJI related death, prosthesis removal or the need for suppressive antibiotic therapy. LA PJI was defined as acute symptoms <3 weeks in patients more than 3 months after the index surgery and with a history of normal joint function. 445 patients were included, comprising 340 cases treated with DAIR and 105 cases treated with implant removal (19% one-stage revision (n = 20), 74.3% two-stage revision (n = 78) and 6.7% definitive implant removal (n = 7). Overall failure in patients treated with DAIR was 45.0% (153/340) compared to 24.8% (26/105) for implant removal (p < 0.001). Difference in failure rate remained after 1:1 propensity-score matching. A preoperative CRIME80-score ≥3 (OR 2.9), PJI caused by S. aureus (OR 1.8) and implant retention (OR 3.1) were independent predictors for failure in the multivariate analysis. DAIR is a viable surgical treatment for most patients with LA PJI, but implant removal should be considered in a subset of patients, especially in those with a CRIME80-score ≥3.
Identifiants
pubmed: 31319141
pii: S0163-4453(19)30198-7
doi: 10.1016/j.jinf.2019.07.003
pii:
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
199-205Informations de copyright
Copyright © 2019 The British Infection Association. Published by Elsevier Ltd. All rights reserved.